By MTT assay, we found that overexpression of POLE-P286R, R375Q, and P452L significantly increased IC50 values of cisplatin compared with overexpression of wildtype POLE (Figures 2C, D), suggesting that the hotspot mutations induce cisplatin resistance in endometrial cancer. Here, POLE is linked to endometrial cancer.